Clik here to view.
Mersana Therapeutics prices $75m IPO
Cambridge-based startup Mersana Therapeutics said today that it raised $75 million in an initial public offering. The company sold 5 million shares of common stock at $15 apiece. Mersana, which debuted...
View ArticleClik here to view.
Plant-virus nanoparticles combined with chemo delays tumor progression
Researchers from Case Western Reserve University School of Medicine, Dartmouth Geisel School of Medicine and RWTH Aachen University have demonstrated that injecting nanoscale potato-virus particles and...
View ArticleClik here to view.
Dissolvable microneedle patch for flu vaccine succeeds in Phase I
Dissolvable microneedle patches that deliver the flu vaccine could provide a safe and cost-effective alternative to traditional immunization methods, according to the results from a Phase I trial...
View ArticleClik here to view.
NY Rep. Collins loses millions on Innate flop
Earlier this year, Rep. Chris Collins’ (R-NY) 16.8% stake in Innate Immunotherapeutics (ASX:IIL) was worth $45.5 million. But since the Australian biotech’s lead drug failed in a 93-patient trial this...
View ArticleClik here to view.
Topical post-herpetic neuralgia treatment fails to meet primary endpoint in...
Teva Pharmaceuticals (NYSE:TEVA) and Xenon Pharmaceuticals (NSDQ:XENE) said this week that the Phase II study of a topical post-herpetic neuralgia treatment did not meet its primary or secondary...
View ArticleClik here to view.
MetaStat lands $7m for personalized cancer diagnostic, therapy tech
MetaStat (OTC:MTST) said this week that it closed the 1st tranche of a $7 million private placement. The round, which was led by Perceptive Advisors, is slated to bring in approximately $2.1 million,...
View ArticleClik here to view.
Researchers develop molecular cage for drug delivery
Researchers from Trinity College Dublin have created a molecular cage that can house different molecules for drug-delivery applications. The cage’s hollow structure, made up of sub-cages, enables...
View ArticleClik here to view.
LipoSeuticals closes Series A for novel drug delivery tech
LipoSeuticals said today that it closed a financing round for an undisclosed amount led by Hong Kong-based life sciences fund, Delos Capital. The company has developed a sugar-lipid polymer-based...
View ArticleClik here to view.
Windtree Therapeutics touts Phase II data for inhaled surfactant
Windtree Therapeutics (NSDQ:WINT) reported data today from the 221-patient Phase IIb trial of its aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. The...
View ArticleClik here to view.
Roche buys mySugr diabetes app
Swiss drugmaker Roche (PINK:RHHBY) said today that it bought diabetes management platform mySugr for an undisclosed price. The 2 companies have worked together since 2014. mySugr’s digital tech enables...
View ArticleClik here to view.
CMS spikes Medicare Advantage data release at the last minute
Medicare Advantage, privately run health plans paid for by Medicare, have covered an increasing number of seniors and disabled people in recent years. More than 1/3 of the 58 million Medicare...
View ArticleClik here to view.
Sunovion seeks FDA nod for COPD treatment – again
Sunovion Pharmaceuticals said today that the FDA accepted the revised new drug application for its eFlow chronic obstructive pulmonary disease drug-device combo. The submission follows a complete...
View ArticleClik here to view.
SteadyMed seeks FDA nod for Trevyent drug-device combo
SteadyMed (NSDQ:STDY) said today that it submitted a new drug application to the FDA for its drug-device pulmonary arterial hypertension therapy. The San Ramon, Calif.-based company’s lead product...
View ArticleClik here to view.
Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug
Ipsen (EPA:IPN) said today that Teijin Pharma Ltd. won approval from the Japanese Ministry of Health, Labor and Welfare for Ipsen’s Somatuline as a therapy for gastroenteropancreatic neuroendocrine...
View ArticleClik here to view.
GSK inks deal for AI-driven drug discovery
Exscientia inked a drug discovery collaboration with GlaxoSmithKline (NYSE:GSK) that could bring the Scotland-based company up to $37.5 million. As a part of the deal, Exscientia plans to use its...
View ArticleClik here to view.
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Novo Nordisk (NYSE:NVO) touted data today from 2 Phase IIIb trials comparing Tresiba insulin degludec to insulin glargine in adults with Type I and Type II diabetes. The results were published in the...
View ArticleClik here to view.
Antibody could be first new mechanism of action for HIV treatment in 10 years
Theratechnologies (TSE:TH) said today that the FDA granted priority review to the biologics license application for ibalizumab as a treatment for multi-drug resistant HIV-1. If the monoclonal antibody...
View ArticleClik here to view.
SICPA aims to arm companies against counterfeit drugs, devices
Counterfeit drugs and medical devices are a pervasive problem for the pharmaceutical industry and for consumers. It’s an issue that affects countries around the world, according to SICPA, a firm that...
View ArticleClik here to view.
Diasome lands $30m to fund clinical trials of liver-targeted insulin
Diasome Pharmaceuticals said today that it inked a funding deal that could bring the company up to $30 million. The round was led by Medicxi and contributed to by JDRF T1D Fund, Black Beret Life...
View ArticleClik here to view.
Aequus to launch trial for anti-nausea patch
Aequus Pharmaceuticals (CVE:AQS) said today that it won approval from Health Canada to launch a proof-of-concept trial to evaluate the bioavailability and safety of the company’s long-acting...
View Article